单位:[1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China华中科技大学同济医学院附属同济医院药学部[2]Statistical Department, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China华中科技大学同济医学院附属同济医院[3]School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Objective This cross-sectional study aimed at investigating the intervention status and the influence of oncologists on oxaliplatin-induced hypersensitivity reactions (OIHR).Methods Snowball sampling was used to send questionnaires to oncologists in various provinces and cities in China, via the internet, to collect data on their socio-demographic characteristics, the occurrence of OIHR, and the current status of interventions. One-way ANOVA and T-test of geographic samples were used to explore the relationship between the incidence of OIHR and intervention measures. Results A total of 401 valid questionnaires were collected, most respondents were 30–40 years old, and most oncologists had 5 years of working experience. The proportions of glucocorticoid and H1 receptor antagonist use for OIHR prevention were 67.83% and 38.65%, respectively. The proportion of oncologists with longer working years and higher professional titles who used glucocorticoids for OIHR prevention was higher, and the observed OIHR incidence was lower. Pretreatment with glucocorticoids may be an effective preventive measure and can reduce the incidence of the OXA allergic reactions (P < 0.05). Conclusion The risk awareness of junior oncologists to OIHR prevention should be strengthened, and clinical efficacy evaluation of glucocorticoids in OIHR prevention should be further promoted.
基金:
Hubei Center for Adverse drug reaction Monitoring (No. 20160422), the funding for research-oriented
clinician plan of Tongji Medical College, Huazhong University of Science and Technology (No. 5001540076), and the Health Research Fund
of Hubei Province (No. WJ2019M117).
语种:
外文
第一作者:
第一作者单位:[1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
通讯作者:
推荐引用方式(GB/T 7714):
Min Li,Wei Li,Yue Wang,et al.Intervention for oxaliplatin-induced hypersensitivity in China: a cross-sectional internet-based survey[J].Oncology and Translational Medicine.2020,6(6):277-281.doi:10.1007/s10330-020-0443-3.
APA:
Min Li,Wei Li,Yue Wang,Xiaofang Shangguan,Rui Huang...&Chengliang Zhang.(2020).Intervention for oxaliplatin-induced hypersensitivity in China: a cross-sectional internet-based survey.Oncology and Translational Medicine,6,(6)
MLA:
Min Li,et al."Intervention for oxaliplatin-induced hypersensitivity in China: a cross-sectional internet-based survey".Oncology and Translational Medicine 6..6(2020):277-281